| Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies MA Nalls, C Blauwendraat, CL Vallerga, K Heilbron, S Bandres-Ciga, ... The Lancet Neurology 18 (12), 1091-1102, 2019 | 1529 | 2019 |
| Novel PINK1 mutations in early‐onset parkinsonism Y Hatano, Y Li, K Sato, S Asakawa, Y Yamamura, H Tomiyama, ... Annals of neurology 56 (3), 424-427, 2004 | 369 | 2004 |
| Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses A Achiron, U Gabbay, R Gilad, S Hassin-Baer, Y Barak, M Gornish, ... Neurology 50 (2), 398-402, 1998 | 367 | 1998 |
| Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia C Blauwendraat, X Reed, L Krohn, K Heilbron, S Bandres-Ciga, M Tan, ... Brain 143 (1), 234-248, 2020 | 178 | 2020 |
| Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis G Yahalom, R Tsabari, N Molshatzki, L Ephraty, H Cohen, S Hassin-Baer Clinical neuropharmacology 36 (3), 78-83, 2013 | 127 | 2013 |
| Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis I Agalliu, M San Luciano, A Mirelman, N Giladi, B Waro, J Aasly, ... JAMA neurology 72 (1), 58-65, 2015 | 119 | 2015 |
| Identification of candidate Parkinson disease genes by integrating genome-wide association study, expression, and epigenetic data sets DA Kia, D Zhang, S Guelfi, C Manzoni, L Hubbard, RH Reynolds, J Botía, ... JAMA neurology 78 (4), 464-472, 2021 | 115 | 2021 |
| SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease RN Alcalay, V Mallett, B Vanderperre, O Tavassoly, Y Dauvilliers, RYJ Wu, ... Movement Disorders 34 (4), 526-535, 2019 | 104 | 2019 |
| Test–retest reliability of UPDRS‐III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: An argument against multiple baseline assessments LV Metman, B Myre, N Verwey, S Hassin‐Baer, J Arzbaecher, D Sierens, ... Movement disorders 19 (9), 1079-1084, 2004 | 92 | 2004 |
| The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers R Inzelberg, OS Cohen, J Aharon-Peretz, I Schlesinger, ... Neurology 78 (11), 781-786, 2012 | 91 | 2012 |
| Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson’s Disease N Kaplan, A Vituri, AD Korczyn, OS Cohen, R Inzelberg, G Yahalom, ... Journal of Molecular Neuroscience 53, 183-188, 2014 | 89 | 2014 |
| Clinical characteristics of neuroleptic-induced parkinsonism S Hassin-Baer, P Sirota, AD Korczyn, TA Treves, B Epstein, H Shabtai, ... Journal of neural transmission 108, 1299-1308, 2001 | 87 | 2001 |
| Botulinum toxin injections for children with excessive drooling S Hassin-Baer, E Scheuer, AS Buchman, I Jacobson, B Ben-Zeev Journal of child Neurology 20 (2), 120-123, 2005 | 85 | 2005 |
| PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations Y Hatano, K Sato, B Elibol, H Yoshino, Y Yamamura, V Bonifati, ... Neurology 63 (8), 1482-1485, 2004 | 84 | 2004 |
| Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism E Moro, J Volkmann, IR Konig, S Winkler, A Hiller, S Hassin-Baer, ... Neurology 70 (14), 1186-1191, 2008 | 81 | 2008 |
| The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease S Bandres‐Ciga, S Saez‐Atienzar, L Bonet‐Ponce, K Billingsley, D Vitale, ... Movement Disorders 34 (4), 460-468, 2019 | 78 | 2019 |
| Neuropsychiatric and cognitive features in autosomal‐recessive early parkinsonism due to PINK1 mutations L Ephraty, O Porat, D Israeli, OS Cohen, O Tunkel, S Yael, Y Hatano, ... Movement Disorders 22 (4), 566-569, 2007 | 78 | 2007 |
| Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies L Krohn, TN Öztürk, B Vanderperre, B Ouled Amar Bencheikh, JA Ruskey, ... Annals of neurology 87 (1), 139-153, 2020 | 77 | 2020 |
| Enhanced creative thinking under dopaminergic therapy in Parkinson disease A Faust‐Socher, YN Kenett, OS Cohen, S Hassin‐Baer, R Inzelberg Annals of neurology 75 (6), 935-942, 2014 | 74 | 2014 |
| Frequency of loss of function variants in LRRK2 in Parkinson disease C Blauwendraat, X Reed, DA Kia, Z Gan-Or, S Lesage, L Pihlstrĝm, ... JAMA neurology 75 (11), 1416-1422, 2018 | 73 | 2018 |
